Adaptimmune Therapeutics PLC (ADAPY): Operating Cash Flow
Not updated since 2024-12-31. No annual report in US GAAP has been filed since. Companies that switch to IFRS reporting, as many foreign filers do, or stop filing are not updated here.
-$73.21M
Year ended 2024-12-31
| Period ended | Operating Cash Flow | Change YoY | Source filing |
|---|---|---|---|
| 2024-12-31 | -$73.21M | n/m | 2025-03-24, From 2024-01-01 |
| 2023-12-31 | -$140.88M | n/m | 2025-03-24, From 2023-01-01 |
| 2022-12-31 | -$141.77M | n/m | 2025-03-24, From 2022-01-01 |
| 2021-12-31 | $10.73M | n/m | 2024-03-06, From 2021-01-01 |
| 2020-12-31 | -$53.59M | n/m | 2023-03-06, From 2020-01-01 |
| 2019-12-31 | -$112.51M | n/m | 2022-03-14, From 2019-01-01 |
| 2018-12-31 | -$104.39M | n/m | 2021-02-25, From 2018-01-01 |
| 2017-12-31 | -$54.31M | n/m | 2019-02-27, From 2017-01-01 |
| 2016-12-31 | -$48.17M | n/a | 2019-02-27, From 2016-01-01 |
| No annual figure between 2015-06-30 and 2016-12-31. | |||
| 2015-06-30 | -$29.67M | n/m | 2018-03-15, From 2014-07-01 |
| 2014-06-30 | $36.84M | n/a | 2017-03-13, From 2013-07-01 |